Pharmacological chaperone therapy using migalastat: 1 year experience of starting a new therapy as reported by Fabry patients at a single UK centre

被引：0
|
作者：
Grillo, Giuseppina [1 ]
机构：
[1] Royal Free Hosp, LSDysosomal Isease Unit, London, England
来源：
MOLECULAR GENETICS AND METABOLISM | 2019年 / 126卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2018.12.151
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
135
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [1] Adherence to a pharmacological chaperone therapy among patients with Fabry disease: One centre experience
    Gorton, Janet
    Forshaw-Hulme, Stuart
    Jones, Mairead
    Jovanovic, Ana
    Stepien, Karolina
    [J]. MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S63 - S63
  • [2] A retrospective outcome analysis of chaperone therapy in Fabry disease: Clinical outcomes after the first year of therapy - A single centre experience
    Orsborne, Chris
    Thompson, Lorraine
    Jovanovic, Ana
    [J]. MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S123 - S123
  • [3] Fabry disease biomarkers in patients switched from enzyme replacement therapy to migalastat oral chaperone therapy
    Auray-Blais, Christiane
    Lavoie, Pamela
    Martineau, Tristan
    Ntumba, Georges Kabala
    Gamrani, Mohamed
    Khan, Aneal
    Altarescu, Gheona
    Lehman, Anna
    Goker-Alpan, Ozlem
    Nowak, Albina
    West, Michael L.
    Bichet, Daniel G.
    [J]. BIOANALYSIS, 2023, 15 (23) : 1421 - 1437
  • [4] A PHARMACOGENETIC APPROACH TO THE SELECTION OF FABRY PATIENTS FOR PHARMACOLOGICAL CHAPERONE THERAPY
    Benjamin, E. R.
    Wu, X.
    Katz, E.
    Mascioli, K.
    Della Valle, M. C.
    Chang, H.
    Greene, D.
    Schiffmann, R.
    Lockhart, D. J.
    Valenzano, K. J.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 : S152 - S152
  • [5] Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year
    Muentze, Onas
    Gensler, Daniel
    Maniuc, Octavian
    Liu, Dan
    Cairns, Tereza
    Oder, Daniel
    Hu, Kai
    Lorenz, Kristina
    Frantz, Stefan
    Wanner, Christoph
    Nordbeck, Peter
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (05) : 1224 - 1233
  • [6] Migalastat: Single centre experience of adult patients with Fabry disease from the Royal Free London NHS Foundation Trust, UK
    Ramaswami, Uma
    Mckie, Mark
    Grillo, Giuseppina
    Mehta, Atul
    Hughes, Derralynn
    [J]. MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S121 - S121
  • [7] First experience of switching from enzyme replacement therapy to oral chaperone migalastat for treating Fabry disease in Korea
    Cheon, Chong Kun
    Yoo, Sukdong Yoo
    [J]. MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S24 - S25
  • [8] Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease
    Lukas, Jan
    Cimmaruta, Chiara
    Liguori, Ludovica
    Pantoom, Supansa
    Iwanov, Katharina
    Petters, Janine
    Hund, Christina
    Bunschkowski, Maik
    Hermann, Andreas
    Cubellis, Maria Vittoria
    Rolfs, Arndt
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [9] ENZYME REPLACEMENT THERAPY AND ITS EFFECTS ON PROGRESSION OF FABRY DISEASE, A SINGLE CENTRE EXPERIENCE
    Oliver, M.
    Sharma, R.
    Hendriksz, C. J.
    Jovanovic, A.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 : S147 - S147
  • [10] Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 30-month results from the randomized phase 3 ATTRACT study
    Feldt-Rasmussen, Ulla
    Hughes, Derralynn
    Sunder-Plassmann, Gere
    Shankar, Suma
    Olivotto, Iacopo
    Ortiz, Damara
    Lachmann, Robin H.
    Ohashi, Toya
    Hamazaki, Takashi
    Skuban, Nina
    Yu, Julie
    Barth, Jay A.
    Nicholls, Kathleen
    [J]. MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S53 - S53
12345